ER4 Stock Chart & Stats
CHF3.89
--
Market closed
CHF3.89
--
Day’s Range― - ―
52-Week RangeCHF3.58 - CHF5.78
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
CHF287.46M
Enterprise ValueCHF879.71
Total Cash (Recent Filing)CHF139.70M
Total Debt (Recent Filing)CHF581.80M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 11, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.44
Shares Outstanding51,273,335
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)1.27
Price to Sales (P/S)0.89
P/FCF Ratio4.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF8.28Price Target Upside112.92% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)0.29
Revenue Forecast (FY)CHF525.36M
Bulls Say, Bears Say
Bulls Say
Government MCM DemandStrong medical-countermeasure demand and repeated government contract awards support a durable role in biodefense procurement. The breadth of ACAM2000, botulism and other products can provide revenue visibility beyond commercial channels, although delivery timing remains important.
Positive Cash GenerationPositive operating and free cash flow, despite a reported TTM net loss, demonstrates that the business is still converting activity into liquidity. This supports ongoing operations and reduces near-term reliance on external financing, though the recent decline in free cash flow warrants monitoring.
Biodefense Portfolio PositionA broad medical-countermeasure portfolio addressing high-consequence threats, combined with deep U.S. and allied government relationships, supports strategic relevance. Recent ACAM2000 approvals in Saudi Arabia and Singapore also expand potential procurement channels and reinforce international positioning.
Bears Say
Naloxone CompetitionNew OTC and prescription naloxone entrants create a structural challenge to NARCAN’s commercial franchise rather than a temporary sales fluctuation. Greater competition and price pressure can reduce volume, revenue quality and future cash contribution from an important product.
Unstable ProfitabilityPersistent and forecast GAAP losses indicate that improved revenue and adjusted margins are not yet translating into durable bottom-line earnings. The large NARCAN impairment also reflects lower expected future cash flows, highlighting weaker profitability and earnings visibility.
Elevated LeverageHigher leverage relative to equity reduces financial flexibility while profitability remains negative and free cash flow has recently declined. Debt refinancing and liquidity actions provide support, but the capital structure still leaves less capacity to absorb weaker product performance or fund growth.
Emergent Biosolutions News
ER4 FAQ
What was Emergent Biosolutions’s price range in the past 12 months?
Emergent Biosolutions lowest stock price was CHF3.58 and its highest was CHF5.78 in the past 12 months.
What is Emergent Biosolutions’s market cap?
Emergent Biosolutions’s market cap is CHF287.46M.
When is Emergent Biosolutions’s upcoming earnings report date?
Emergent Biosolutions’s upcoming earnings report date is Nov 11, 2026 which is in 46 days.
How were Emergent Biosolutions’s earnings last quarter?
Emergent Biosolutions released its earnings results on Aug 05, 2026. The company reported CHF0.48 earnings per share for the quarter, beating the consensus estimate of -CHF0.068 by CHF0.548.
Is Emergent Biosolutions overvalued?
According to Wall Street analysts Emergent Biosolutions’s price is currently Undervalued.
Does Emergent Biosolutions pay dividends?
Emergent Biosolutions does not currently pay dividends.
What is Emergent Biosolutions’s EPS estimate?
Emergent Biosolutions’s EPS estimate is -0.31.
How many shares outstanding does Emergent Biosolutions have?
Emergent Biosolutions has 51,273,335 shares outstanding.
What happened to Emergent Biosolutions’s price movement after its last earnings report?
Emergent Biosolutions reported an EPS of CHF0.48 in its last earnings report, beating expectations of -CHF0.068. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Emergent Biosolutions?
Currently, no hedge funds are holding shares in CH:ER4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emergent Biosolutions Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF8.28 (112.92% Upside)
CHF8.28 (112.92% Upside)
Blogger Sentiment
Neutral
CH:ER4 Sentiment 67%
Sector Average 63%
Sector Average 63%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Emergent Biosolutions
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
ER4 Company Deck
ER4 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a balance of strong near-term operational execution and financial results—Q2 revenue and adjusted EBITDA materially exceeded expectations, driven by accelerated MCM deliveries and improved margins—alongside significant commercial headwinds in the naloxone business that prompted a $191M noncash impairment and a downward revision to full-year revenue and profitability guidance. Management is taking proactive restructuring and capital allocation actions (debt refinancing, share repurchases, $40M annualized cost-savings plan) to preserve liquidity and position the company for 2027, but the naloxone competitive dynamics and guidance cuts temper the otherwise strong quarter.View all CH:ER4 earnings summariesER4 Stock 12 Month Forecast
Average Price Target
CHF8.28
▲(112.92% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―